Nature medicine · 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
СтатьяКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gion María, Blancas Isabel, Cortez-Castedo Patricia, Cortés-Salgado Alfonso, Marmé Frederik, Blanch Salvador, Morales Serafín, Díaz Nieves, Calvo-Plaza Isabel, Recalde Sabela, Martínez-Bueno Alejandro, Ruiz-Borrego Manuel, Llabrés Elisenda, Taberner María Teresa, de Laurentiis Michelino, García-Vicente Silvia, Guerrero José Antonio, Boix Olga, Rodríguez-Morató Jose, Sampayo-Cordero Miguel, Antonarelli Gabriele, Pérez-García José Manuel, Cortés Javier, Llombart-Cussac Antonio, ATRACTIB Trial Investigators
Аннотация
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis. The current first-line treatment for advanced TNBC (aTNBC) is determined by the expression of programmed cell death-ligand 1 (PD-L1). In the ATRACTIB trial-a multicenter, single-arm, phase 2 study-we evaluated the combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment for patients with aTNBC, independently of PD-L1 status. The primary endpoint was investigator-assessed progression-free survival. One hundred female patients were enrolled, with most evaluable tumors being PD-L1-negative (97.6%). The primary endpoint was met, with a median progression-free survival of 11.0 months (95% confidence interval (CI): 9.0-13.4; P < 0.001). The objective response rate was 63.0% (95% CI: 52.8-72.4) and median overall survival was 27.4 months (95% CI: 23.4-37.4). No treatment-related deaths or new safety signals were observed. This combination demonstrated significant antitumor activity as first-line therapy for aTNBC patients and merits further investigation. ClinicalTrials.gov Identifier: NCT04408118 .